You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 23 No. 5, November 1970 TABLE OF CONTENTS
  Archives
  •  Online Features
  ORIGINAL ARTICLES
 This Article
 •References
 •Full text PDF
 • Reply to article
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati
What's this?

Immunosuppression and the Guillain-Barré Syndrome

David A. Drachman, MD; Philip Y. Paterson, MD; Byron S. Berlin, MD; Jadwiga Roguska, MD

Arch Neurol. 1970;23(5):385-393.

Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

ALTHOUGH idiopathic polyneuritis, or the "Landry-Guillain-Barré (LGB) syndrome" has been known for more than 100 years,1 its nosologic limits, etiology, and treatment remain a matter of controversy.2-23 Current opinion favors an autoallergic pathogenesis, and many authors have drawn attention to experimental allergic neuritis (EAN) first described by Waksman and Adams24 as the appropriate experimental model of this clinical condition.12,14-17 As a natural outgrowth of this concept, immunosuppressive treatment has been suggested as specific therapy for the LGB syndrome. Experimentally, steroids have been shown to prevent EAN,25 and both steroids and immunosuppressive drugs will prevent the closely related experimental allergic encephalomyelitis (EAE) consistently in animals.26-30 With but one exception,31 the drugs are effective only if given before the onset of clinical evidence of paralysis. The use of steroids and adrenocorticotropic hormone in humans with idiopathic polyneuritis has been less successful, however.5,7,10,12,-17,21-23,32 . . . [Full Text PDF of this Article]


Author Affiliations

Chicago

From the Department of Neurology (Dr. Drachman); the Section of Infectious Diseases—Hypersensitivity, Department of Medicine (Dr. Paterson); Northwestern University Clinical Virology Laboratory, departments of medicine and pathology (Dr. Berlin); and the Renal Section, Department of Medicine (Dr. Roguska); Northwestern University McGaw Medical Center, Chicago.


Footnotes

Accepted for publication June 13, 1970.

Read in part before the 22nd annual meeting of the American Academy of Neurology, Bal Harbour, Fla, May 2, 1970.

Reprint requests to Northwestern University Medical School, 303 E Chicago Ave, Chicago 60611 (Dr. Drachman).



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati     What's this?





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 1970 American Medical Association. All Rights Reserved.